Klivira
Request demo

Streamlining Humana Ocrevus Prior Authorization Workflows

Successfully managing Humana Ocrevus prior authorization is critical for timely patient access to this essential multiple sclerosis treatment. Klivira integrates with your EMR to automate key steps in this high-volume PA workflow.

Ocrevus (ocrelizumab) is a high-cost, anti-CD20 monoclonal antibody indicated for relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). As an intravenously administered specialty medication, it frequently requires prior authorization (PA) under both commercial and Medicare Advantage plans. For revenue cycle directors and prior authorization coordinators, understanding Humana's specific requirements for Ocrevus is essential to minimize delays and denials.

Understanding Humana's Prior Authorization Channels for Ocrevus

For Ocrevus, typically covered under the medical benefit, Humana primarily directs medical PA submissions through Availity Essentials. This portal facilitates PA initiation, eligibility verification, and document submission. Alternatively, providers can submit X12 278 transactions via clearinghouses. For specific plans where Ocrevus might fall under the pharmacy benefit, CenterWell Specialty Pharmacy manages specialty injectables, with retail pharmacy PA routing through CoverMyMeds or Surescripts ePA.

Key Medical Necessity Criteria and Policy Access

Humana publishes medical policies and coverage determinations on its provider site, which should be referenced by specific policy number and effective date. For Medicare Advantage plans, coverage policies must align with CMS National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs). Criteria for specialty drugs like Ocrevus often include specific diagnostic confirmation, disease progression, and trial/failure of alternative therapies. Humana's medical policies may be internally developed, MCG-based, or NCCN-compendium-based, as disclosed within the policy.

Common Denial Reasons for Ocrevus Under Humana

  • **Lack of Medical Necessity:** Insufficient clinical documentation to support the diagnosis or treatment rationale per Humana's medical policy.
  • **Insufficient Documentation:** Missing or incomplete clinical notes, lab results, or imaging studies required for review.
  • **NCD/LCD Non-Coverage:** For Medicare Advantage plans, non-compliance with applicable Medicare National or Local Coverage Determinations.
  • **Step Therapy Requirements:** Failure to document trial and failure of preferred alternative therapies, if applicable to the plan's formulary.
  • **Site-of-Service Mismatch:** Administration at a facility type not approved or preferred by Humana for specialty infusions.

Expedited Review and Appeal Pathways

When a delay in the standard PA process could seriously jeopardize a patient's life or health, providers can request an expedited review. Humana's turnaround timeframes are published on its provider site. For denied Ocrevus authorizations, Humana outlines a clear appeal pathway in its provider manual. Medicare Advantage appeals follow the CMS-mandated 5-level process, starting with reconsideration. Peer-to-peer review options are typically available to discuss clinical rationale directly with a Humana medical director.

Klivira's Role in Automating Ocrevus PA for Humana

Klivira's platform automates the complex Humana Ocrevus prior authorization process by integrating directly with your EMR and connecting to payer portals like Availity via secure, compliant channels. We streamline data extraction, form submission, and status tracking, reducing manual effort and accelerating approval times. Our system supports X12 278 transactions and monitors for CMS-0057-F compliance for Medicare Advantage plans, ensuring your workflows align with evolving regulatory requirements.

Frequently asked questions

What documentation is typically required for Humana Ocrevus prior authorization?

Required documentation generally includes clinical notes detailing diagnosis (RMS or PPMS), MRI reports demonstrating disease activity, confirmation of previous therapies and their outcomes, and a comprehensive treatment plan. Always consult the specific Humana medical policy for Ocrevus to ensure all criteria are met.

How does CMS-0057-F impact Humana Ocrevus prior authorizations for Medicare Advantage patients?

As an impacted payer under CMS-0057-F, Humana's Medicare Advantage plans are subject to new requirements, including tightened standard PA decision timeframes (7 calendar days) and electronic PA API conformance by 2027. This rule aims to streamline the PA process and improve transparency for specialty drugs like Ocrevus.

Can Ocrevus be covered under Humana's pharmacy benefit instead of the medical benefit?

While Ocrevus is typically a medical benefit drug due to its intravenous administration, specific Humana plans or formularies might occasionally place certain specialty injectables under the pharmacy benefit. CenterWell Specialty Pharmacy handles pharmacy benefit specialty drugs. Always verify the specific patient's plan benefits and formulary for accurate coverage information.

What is the process for a peer-to-peer review for a denied Ocrevus PA with Humana?

If an Ocrevus prior authorization is denied, you can typically request a peer-to-peer (P2P) review. This involves a discussion between the prescribing physician and a Humana medical director to present additional clinical information or clarify the medical necessity. Details on how to initiate a P2P review are available in Humana's provider manual.

Related coverage

Other ocrevus prior authorization by payer

Other ocrevus prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo